Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quantitative structure-activity relationship studies on cholecystokinin antagonists.

Satya P Gupta1

  • 1Department of Chemistry, Birla Institute of Technology and Science, Pilani, India. spg@bits-pilani.ac.in

Current Pharmaceutical Design
|January 29, 2002
PubMed
Summary

Quantitative structure-activity relationship (QSAR) studies reveal key interactions for cholecystokinin (CCK) antagonists. Different chemical classes, like benzodiazepines and quinazolinones, bind to CCK receptors through distinct forces, guiding drug design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

QSAR Studies to Predict Activity of HSP90 Inhibitors.

Current topics in medicinal chemistry·2021
Same author

Molecular Processes Exploited as Drug Targets for Cancer Chemotherapy.

Anti-cancer agents in medicinal chemistry·2020
Same author

An Overview of Ovarian Cancer: Molecular Processes Involved and Development of Target-based Chemotherapeutics.

Current topics in medicinal chemistry·2020
Same author

Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.

Current topics in medicinal chemistry·2020
Same author

In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors.

Combinatorial chemistry & high throughput screening·2020
Same author

Advances in Studies on Neurodegenerative Diseases and their Treatments.

Current topics in medicinal chemistry·2020

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Computational Chemistry

Background:

  • Cholecystokinin (CCK) is a peptide hormone with receptors in both the central and peripheral nervous systems.
  • CCK-A and CCK-B receptors are distinct, with CCK-B receptors showing structural similarity to gastrin receptors.
  • CCK antagonists are investigated for therapeutic potential, necessitating an understanding of their receptor interactions.

Purpose of the Study:

  • To review quantitative structure-activity relationship (QSAR) studies on various classes of cholecystokinin antagonists.
  • To elucidate the specific binding mechanisms and interactions of different antagonist categories with CCK receptors.
  • To provide insights for the rational design of novel CCK receptor modulators.

Main Methods:

Related Experiment Videos

  • Review of existing QSAR studies on cholecystokinin antagonists.
  • Analysis of structure-activity relationships for diverse chemical classes including benzodiazepines, amino acid derivatives, quinazolinones, and peptide analogs.
  • Identification of key molecular interactions (hydrophobic, hydrogen bonding, dispersion, steric) governing antagonist activity.

    • Main Results:

    • QSAR studies confirm structural relationships between CCK-B and gastrin receptors.
    • Benzodiazepine antagonists primarily utilize hydrophobic interactions and hydrogen bonding for receptor binding.
    • Quinazolinone antagonists rely mainly on hydrogen bonding, while glutamic acid analogs involve hydrophobic and dispersion forces. Steric factors are crucial for peptide analogs.

    Conclusions:

    • Different classes of CCK antagonists exhibit distinct binding modes and key interaction forces with CCK receptors.
    • Understanding these structure-activity relationships is crucial for the development of selective and potent CCK receptor antagonists.
    • QSAR studies provide valuable frameworks for the design of targeted therapeutics modulating CCK signaling pathways.